Approximately 15% to 20% of breast cancer cases are classified as triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and HER2 expression [23]. This evidence concerns the gene ERBB2 and breast cancer.